This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	BRAF; neuroblastoma RAS viral oncogene (NRAS)	Selective imidazo(4,5)pyridin-2-one-based inhibitors of mutant BRAF could help treat cancer. In a growth inhibition assay, 2 of the compounds had 11 times and 53 times greater activity in cells expressing mutant BRAF than in cells with mutant NRAS and wild-type BRAF, respectively. Next steps include seeking a commercial partner to carry out late-stage preclinical and clinical development of candidate mutant BRAF inhibitors. SciBX 3(11); doi:10.1038/scibx.2010.336 Published online March 18, 2010	Multiple patents filed covering composition of matter and medical uses; available for licensing	Nourry, A. <i>et al. J. Med. Chem.</i> ; published online Feb. 11, 2010; doi:10.1021/jm901509a Contact: Caroline J. Springer, Cancer Research UK Centre for Cell and Molecular Biology, The Institute of Cancer Research, London, U.K. e-mail: caroline.springer@icr.ac.uk